BCL2 and lymphoma: Recently, a group of natural products (Rocaglates) and their synthetic derivatives have been emerging as promising therapeutical agents for the treatment of MYC-associated lymphoma, especially those Double Hit lymphoma with concurrent MYC and BCL2 dysregulation [222, 223].